Revance Therapeutics, a company deriving new methods for delivering botox across skin membranes (moving away from needles), has raised $25.6 million in a fourth round of venture funding, according to a filing with the SEC. Based in Newark, Calif., the company is backed by a large flock of investors, including Essex Woodlands Health Ventures, Vivo Ventures, Technology Partners, Bio*One Capital, Medicis Pharmaceutical, Palo Alto Investors, Pac-Link Management, Shepherd Ventures, Leader Ventures and Horizon Technology Finance.